JP2024509981A5 - - Google Patents

Info

Publication number
JP2024509981A5
JP2024509981A5 JP2023556474A JP2023556474A JP2024509981A5 JP 2024509981 A5 JP2024509981 A5 JP 2024509981A5 JP 2023556474 A JP2023556474 A JP 2023556474A JP 2023556474 A JP2023556474 A JP 2023556474A JP 2024509981 A5 JP2024509981 A5 JP 2024509981A5
Authority
JP
Japan
Prior art keywords
alkyl
membered
pharmaceutically acceptable
hydrogen
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023556474A
Other languages
English (en)
Japanese (ja)
Other versions
JP7659648B2 (ja
JP2024509981A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/052281 external-priority patent/WO2022195454A1/en
Publication of JP2024509981A publication Critical patent/JP2024509981A/ja
Publication of JP2024509981A5 publication Critical patent/JP2024509981A5/ja
Priority to JP2025056015A priority Critical patent/JP2025106341A/ja
Application granted granted Critical
Publication of JP7659648B2 publication Critical patent/JP7659648B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023556474A 2021-03-15 2022-03-14 ピラゾロピリジン誘導体及びその使用 Active JP7659648B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025056015A JP2025106341A (ja) 2021-03-15 2025-03-28 ピラゾロピリジン誘導体及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163161139P 2021-03-15 2021-03-15
US63/161,139 2021-03-15
US202163164130P 2021-03-22 2021-03-22
US63/164,130 2021-03-22
PCT/IB2022/052281 WO2022195454A1 (en) 2021-03-15 2022-03-14 Pyrazolopyridine derivatives and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025056015A Division JP2025106341A (ja) 2021-03-15 2025-03-28 ピラゾロピリジン誘導体及びその使用

Publications (3)

Publication Number Publication Date
JP2024509981A JP2024509981A (ja) 2024-03-05
JP2024509981A5 true JP2024509981A5 (cg-RX-API-DMAC7.html) 2024-03-28
JP7659648B2 JP7659648B2 (ja) 2025-04-09

Family

ID=80819999

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023556474A Active JP7659648B2 (ja) 2021-03-15 2022-03-14 ピラゾロピリジン誘導体及びその使用
JP2025056015A Pending JP2025106341A (ja) 2021-03-15 2025-03-28 ピラゾロピリジン誘導体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025056015A Pending JP2025106341A (ja) 2021-03-15 2025-03-28 ピラゾロピリジン誘導体及びその使用

Country Status (20)

Country Link
US (4) US11787785B2 (cg-RX-API-DMAC7.html)
EP (1) EP4308562A1 (cg-RX-API-DMAC7.html)
JP (2) JP7659648B2 (cg-RX-API-DMAC7.html)
KR (1) KR102902295B1 (cg-RX-API-DMAC7.html)
AU (2) AU2022239950B2 (cg-RX-API-DMAC7.html)
CA (1) CA3208951A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002726A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023013486A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230486A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000188A (cg-RX-API-DMAC7.html)
EC (1) ECSP23076800A (cg-RX-API-DMAC7.html)
IL (1) IL305931A (cg-RX-API-DMAC7.html)
JO (1) JOP20230218A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023010827A (cg-RX-API-DMAC7.html)
PE (1) PE20242203A1 (cg-RX-API-DMAC7.html)
PY (1) PY2217419A (cg-RX-API-DMAC7.html)
TW (1) TWI923713B (cg-RX-API-DMAC7.html)
UY (1) UY39671A (cg-RX-API-DMAC7.html)
WO (1) WO2022195454A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202307290B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021255160B2 (en) 2020-04-13 2024-02-01 Aptabio Therapeutics Inc. Pulmonary fibrosis medicine containing pyrazole derivative
EP4308559A1 (en) * 2021-03-15 2024-01-24 Novartis AG Benzisoxazole derivatives and uses thereof
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
PE20240822A1 (es) 2021-03-22 2024-04-18 Neurocrine Biosciences Inc Inhibidores de vmat2 y metodos de uso
CN120129677A (zh) 2022-11-04 2025-06-10 百时美施贵宝公司 化合物及其用于治疗血红素病变的用途
WO2024255810A1 (en) * 2023-06-15 2024-12-19 Hangzhou Glubio Pharmaceutical Co., Ltd Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof
WO2026136866A1 (en) 2024-12-20 2026-06-25 Prelude Therapeutics Incorporated Kat6 targeting compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
BRPI0417186A (pt) 2003-12-02 2007-03-06 Celgene Corp método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
CN102089291B (zh) 2008-04-28 2016-08-17 杏林制药株式会社 环戊基丙烯酰胺衍生物
EP2165707A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
ES2689429T3 (es) 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
JP2020009513A (ja) * 2018-07-10 2020-01-16 キオクシア株式会社 メモリシステム
AR116109A1 (es) * 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
KR102980990B1 (ko) 2019-04-05 2026-06-25 카이메라 쎄라퓨틱스 인코포레이티드 Stat 분해제 및 이의 용도
EP3969458A4 (en) 2019-05-13 2023-05-17 Borah, Inc. CHEMICAL COMPOUNDS
PH12022551482A1 (en) 2019-12-18 2023-11-29 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4100394B1 (en) 2020-02-04 2026-04-08 Stingray Therapeutics, Inc. Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereof
US20230089530A1 (en) 2020-02-09 2023-03-23 Newave Pharmaceutical Inc. Quinuclidinone analogues as anticancer agents
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.

Similar Documents

Publication Publication Date Title
JP2024520654A5 (cg-RX-API-DMAC7.html)
US11299480B2 (en) 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors
EP3630101B1 (en) Tegavivint for use in the treatment of pulmonary fibrosis
TW200934782A (en) 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use
RU2010126063A (ru) Производные 4-(2-амино-1-гидроксиэтил)фенола как агонисты в2 адренергического рецептора
US11434205B2 (en) Substituted imidazole carboxylate derivatives and the use thereof
RU2006128426A (ru) Производные тиофенав в качестве ингибиторов снк 1
JP2018109017A5 (cg-RX-API-DMAC7.html)
RU2006113700A (ru) Аминозамещенный этиламито-агонисты бэта2-адренергических рецепторов
JP7080346B2 (ja) 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Bclファミリーアンタゴニストであるホスホノアミダート
JP2009526831A5 (cg-RX-API-DMAC7.html)
JP2016128481A (ja) 肺高血圧症の処置のためのニトロキシル供与体
EP4201941B1 (en) Pyrazole boronic acid compound, pharmaceutical composition containing same, and uses thereof
RU2004104329A (ru) Ацилсемикарбазиды как ингибиторы циклинзависимой киназы, полезные в качестве противораковых и противопролиферативных агентов
CN115605210A (zh) 用于治疗心律失常的烟酰胺单核苷酸和双烟酰胺二核苷酸衍生物
JP2004524345A5 (cg-RX-API-DMAC7.html)
JP2024509625A5 (cg-RX-API-DMAC7.html)
JP2017137323A (ja) 新規抗がん剤
JP2022541311A5 (cg-RX-API-DMAC7.html)
JP2026510456A (ja) Ampk活性化および/またはchop阻害により処置できる疾患および障害の処置のためのセフィン1および関連化合物
RU2732417C1 (ru) Производные фенотиазина и способы их применения
WO2022109311A1 (en) Methods and materials for increasing nicotinamide phosphoribosyltransferase activity
JP2008538099A5 (cg-RX-API-DMAC7.html)
US20250002512A1 (en) Novel anti-depressant and neuroplastic agents and therapeutic uses thereof
JP5198852B2 (ja) 脳梗塞に関連する脳血管障害の治療に有用なピラゾロン化合物